% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Prott:1052301,
author = {Prott, Lea S. and Kaldenhoven, Vanessa and Hugger, Alfons
and Langner, Robert and Gierthmuehlen, Petra C. and
Gierthmuehlen, Mortimer},
title = {{T}ranscutaneous {A}uricular {V}agus {N}erve {S}timulation
for the {T}reatment of {M}yoarthropathic {S}ymptoms
{A}ssociated {W}ith {T}emporomandibular {D}isorders—{A}
{P}ilot {R}andomised {C}ontrolled {T}rial},
journal = {Journal of oral rehabilitation},
volume = {52},
number = {12},
issn = {0305-182X},
address = {Oxford [u.a.]},
publisher = {Wiley-Blackwell},
reportid = {FZJ-2026-00916},
pages = {2351 - 2360},
year = {2025},
abstract = {ABSTRACTBackground: Transcutaneous auricular vagus nerve
stimulation (taVNS) is a safe and feasible treatment for a
variety of acuteand chronic pain conditions. However, no
evidence about taVNS effectiveness in patients with chronic
pain associated with tem-poromandibular disorders (TMD) is
available.Objective: To evaluate the feasibility of and
compliance with taVNS in participants experiencing chronic
TMD pain and poten-tial effects on pain, psychological
well-being, muscle activity, and kinematics.Methods: Twenty
adults with chronic TMD pain were randomised to receive
taVNS (n = 10) or sham (n = 10). In the taVNSgroup,
stimulation was performed on the left tragus for 4 h daily
(25 Hz, pulse width 250 μs, 28 s on/32 s off). In the sham
group,an inactive non-functional sham electrode was used.
Patient-reported outcome measures (GCPS, PHQ-9, GAD-7,
PHQ-15, andOHIP- G14), muscle activity, and kinematics were
assessed at baseline, 4 weeks, and 8 weeks. Compliance was
assessed using asmartphone app, which recorded daily
stimulation time and intensity.Results: Recruitment and
retention rates were high $(100\%$ and $90\%,$
respectively), with $83\%$ adherence to the
intervention.Participants receiving taVNS showed a large
effect on oral health-related quality of life, and at least
a small but potentially impor-tant effect on pain intensity,
anxiety, depression, severity of somatic symptoms, muscle
activity, and kinematics. However, noneof these differences
were statistically significant. No serious adverse events
were identified.},
cin = {INM-7},
ddc = {610},
cid = {I:(DE-Juel1)INM-7-20090406},
pnm = {5251 - Multilevel Brain Organization and Variability
(POF4-525) / 5252 - Brain Dysfunction and Plasticity
(POF4-525)},
pid = {G:(DE-HGF)POF4-5251 / G:(DE-HGF)POF4-5252},
typ = {PUB:(DE-HGF)16},
doi = {10.1111/joor.70039},
url = {https://juser.fz-juelich.de/record/1052301},
}